Immuno-oncology Clinical Trials

Immuno-oncology Clinical Trials Market Outlook

The global immuno-oncology clinical trials market is projected to reach USD 44.5 billion by 2035, growing at a CAGR of 10.2% during the forecast period from 2025 to 2035. This remarkable growth can be attributed to the increasing prevalence of various types of cancers, the rising investments in R&D for innovative cancer therapies, and the remarkable advancements in immunotherapy techniques. Additionally, there is an expanding number of clinical trials being conducted at various trial phases, which significantly contributes to the overall growth of the market. The integration of technology in clinical trials, including the use of artificial intelligence and machine learning in trial design and patient recruitment, further enhances the efficiency of these studies, propelling the market forward.

Growth Factor of the Market

The growth of the immuno-oncology clinical trials market can be largely attributed to the continuous advancements in cancer treatment methodologies, particularly the rising use of immunotherapies which are designed to harness the body’s immune system to combat cancer more effectively. The increasing incidence rates of cancer globally has led to greater demand for innovative treatment options, prompting pharmaceutical companies to invest heavily in research and development activities. Moreover, favorable regulatory frameworks in various regions are facilitating the quicker initiation of clinical trials, allowing for rapid advancements in drug approval timelines. Furthermore, collaborations between pharmaceutical companies and academic institutions are fostering a conducive environment for groundbreaking research, thereby accelerating the pace of clinical trials. Additionally, the ability of immuno-oncology therapies to provide better outcomes compared to traditional treatments is attracting significant attention from investors, further driving market growth.

Key Highlights of the Market

• The global immuno-oncology clinical trials market is expected to witness a CAGR of 10.2% from 2025 to 2035.
• North America holds the largest market share, accounting for approximately 50% of the total market revenue in 2025.
• Phase III trials dominate the market, contributing significantly to overall trial volume.
• Monoclonal antibodies are the leading therapy type, driven by their extensive applications across various cancers.
• Collaboration between pharmaceutical companies and research institutes is boosting trial efficacy and innovation.

By Trial Phase

Phase I:

Phase I clinical trials are critical for evaluating the safety and tolerability of new immuno-oncology therapies. These trials primarily focus on determining the maximum tolerated dose (MTD) of a drug and identifying any potential side effects. Phase I trials typically involve a small group of participants, usually between 20 to 80 individuals, who are closely monitored to evaluate their responses to the treatment. The insights gained from Phase I trials directly influence the design and implementation of subsequent phases, thereby playing a pivotal role in the overall clinical trial landscape. As the number of innovative therapies entering the market increases, the demand for Phase I trials continues to rise, contributing significantly to the growth of the immuno-oncology clinical trials market.

Phase II:

Phase II trials involve a larger group of participants, typically ranging from 100 to 300. The primary goal at this stage is to assess the effectiveness of the new immuno-oncology therapies while continuing to monitor safety and side effects. These trials are crucial in determining the optimal dosage and regimen for future studies. During this phase, researchers gather substantial data that aids in evaluating the efficacy of drug candidates against specific cancer types. The increasing number of cancer cases and the urgent need for effective treatments are driving investments in Phase II trials, thus contributing to the overall growth of the immuno-oncology clinical trials market.

Phase III:

Phase III trials are designed to provide comprehensive data on the efficacy and safety of a new therapeutic intervention, often compared to standard treatments. These trials typically involve hundreds to thousands of participants and are pivotal in determining the drug's viability for market approval. The data collected during this phase is critical, as it forms the basis for regulatory submissions and ultimately influences clinical practice guidelines. Given the accelerating pace of cancer drug development and the rising number of investigational new therapies, Phase III trials are increasingly becoming the focal point of immuno-oncology clinical trials, significantly propelling market growth.

Phase IV:

Phase IV trials, also known as post-marketing studies, are conducted after a drug has received regulatory approval. The primary goal of these trials is to monitor long-term effectiveness, safety, and any adverse effects of the therapy in a broader population. They provide invaluable data that can lead to dosage adjustments or additional indications for the drug. As the immuno-oncology landscape evolves, the importance of Phase IV trials is growing, as they help in gathering real-world data that complements pre-approval findings, thus enhancing the overall confidence in these therapies.

Phase V:

Phase V clinical trials, while not as commonly referenced, focus on the comparative effectiveness of a new therapy in the real world against existing therapies. These trials study the drug under conditions that mirror everyday clinical practice, providing insights into how the drug performs outside the controlled environment of clinical trials. As the trend towards personalized medicine grows, Phase V trials are gaining traction as they offer a valuable perspective on the therapy's practicality in routine healthcare settings. This segment of immuno-oncology clinical trials is likely to witness increased attention and investment as stakeholders seek to understand treatment outcomes in diverse patient populations.

By Therapy Type

Monoclonal Antibodies:

Monoclonal antibodies are a cornerstone of immuno-oncology therapies, designed to target specific antigens on cancer cells. These therapies work by either marking cancer cells for destruction by the immune system or blocking proteins that inhibit immune responses. The widespread adoption of monoclonal antibodies in clinical trials can be attributed to their proven efficacy in treating various cancers, such as lymphoma and breast cancer. The ongoing research and development in this area are leading to the emergence of novel monoclonal antibodies that are expected to enhance treatment outcomes, significantly driving the growth of this segment in the immuno-oncology clinical trials market.

Checkpoint Inhibitors:

Checkpoint inhibitors have revolutionized the treatment of cancer by disrupting the mechanisms that allow tumors to evade the immune system. These therapies block proteins that act as brakes on the immune response, allowing T-cells to attack cancer cells more effectively. The success of checkpoint inhibitors has spurred numerous clinical trials aimed at expanding their applications across various cancer types. As a result, this therapy type is experiencing a significant surge in clinical trial activity, contributing to the overall growth of the immuno-oncology market. The promising results from these trials are likely to lead to increased approvals and the development of combination therapies, further driving this segment.

Cancer Vaccines:

Cancer vaccines represent a unique approach to immuno-oncology by stimulating the immune system to target cancer cells. Unlike traditional vaccines that prevent disease, cancer vaccines aim to treat existing cancers by eliciting an immune response. Clinical trials in this area are diverse, including therapeutic vaccines that use cancer-specific antigens. The growing recognition of the potential for cancer vaccines to complement existing therapies is driving interest and investment in this segment. Continued research and successful trial outcomes are expected to pave the way for innovative cancer vaccine options, enhancing their presence in the immuno-oncology clinical trials market.

Cytokines:

Cytokines play a critical role in regulating the immune response, and their application in immuno-oncology is gaining traction. These proteins can enhance the immune system's ability to recognize and destroy cancer cells. Clinical trials involving cytokines have shown promise in boosting the effectiveness of other cancer therapies, leading to a growing interest in their use. The increasing number of ongoing clinical trials targeting various cytokines reflects the potential this therapy type holds for improving patient outcomes. As researchers continue to explore the synergies between cytokines and other immuno-oncology treatments, this segment is expected to see continued advancement and growth.

Adoptive Cell Transfer Therapy:

Adoptive cell transfer therapy involves the extraction and modification of a patient’s immune cells to enhance their cancer-fighting capabilities before reintroducing them into the body. This personalized approach has demonstrated significant success in certain types of cancers, such as melanoma and hematologic malignancies. The increasing number of clinical trials focused on optimizing this therapy type, including the development of CAR-T cell therapies, is contributing to the expansion of the immuno-oncology landscape. As the understanding of the mechanisms underlying immune responses continues to evolve, adoptive cell transfer therapy is likely to take center stage in future clinical trial initiatives.

By Cancer Type

Lung Cancer:

Lung cancer is one of the leading causes of cancer-related deaths globally, driving significant attention and investment in clinical trials focusing on immuno-oncology therapies. The complexity of lung cancer, with its various subtypes, necessitates tailored therapeutic strategies, and immunotherapies have emerged as a critical component of treatment protocols. Clinical trials targeting lung cancer are expanding, with many studies evaluating the efficacy of checkpoint inhibitors and monoclonal antibodies. As researchers strive to improve outcomes for lung cancer patients, this segment is expected to see sustained growth and innovation in immuno-oncology clinical trials.

Breast Cancer:

Breast cancer is another prominent area of focus in immuno-oncology clinical trials. The heterogeneity of breast cancer subtypes presents unique challenges and opportunities for targeted therapies. Immuno-oncology treatments, particularly checkpoint inhibitors and monoclonal antibodies, have shown promising results in clinical trials, leading to their incorporation into treatment regimens. The increasing incidence of breast cancer and the growing demand for personalized treatment options are propelling significant investment in this area, further enhancing the growth of the immuno-oncology clinical trials market.

Prostate Cancer:

Prostate cancer represents a significant segment of the immuno-oncology clinical trials market, with ongoing research aiming to identify effective therapies that can improve patient outcomes. The application of immunotherapies in prostate cancer treatment is being explored through various clinical trials, evaluating the use of checkpoint inhibitors and cancer vaccines. As the understanding of prostate cancer biology evolves, immuno-oncology therapies are positioned to play a pivotal role in addressing this disease, thereby contributing to the overall market growth.

Colorectal Cancer:

Colorectal cancer is a major public health concern, and its high prevalence has led to a surge in clinical trials focusing on immunotherapy. The role of immuno-oncology in treating colorectal cancer is becoming increasingly evident, with many trials assessing the effectiveness of various therapies. The significant burden of colorectal cancer on healthcare systems drives the need for innovative treatment options, making it a key area of focus within the immuno-oncology clinical trials market. As success rates improve, the market for colorectal cancer therapies is anticipated to experience robust growth.

Melanoma:

Melanoma is a type of skin cancer that has seen remarkable advancements through immuno-oncology therapies, particularly with the success of checkpoint inhibitors. The rapidly evolving landscape of melanoma treatment is characterized by ongoing clinical trials evaluating novel therapies and combination approaches. The high incidence of melanoma, coupled with the urgent need for effective treatments, is propelling significant investment in this area. As more breakthrough therapies emerge, melanoma is expected to maintain a strong presence in the immuno-oncology clinical trials market.

By User

Hospitals:

Hospitals are a primary setting for conducting immuno-oncology clinical trials, given their access to diverse patient populations and advanced medical technologies. These institutions play a pivotal role in patient recruitment and trial management, allowing for comprehensive monitoring of treatment efficacy and safety. The integration of immuno-oncology therapies into hospital protocols is on the rise, as healthcare professionals increasingly recognize the potential benefits these treatments offer. As hospitals continue to expand their clinical trial capabilities, their contribution to the growth of the immuno-oncology clinical trials market is expected to be substantial.

Specialty Clinics:

Specialty clinics, particularly those focused on oncology, are integral to the immuno-oncology clinical trials landscape. Their expertise in managing complex cancer treatments allows for the implementation of specialized protocols tailored to patients' needs. The growing number of patients seeking personalized treatment options is driving the demand for trials conducted in these facilities. Specialty clinics often work closely with pharmaceutical companies to facilitate trials, enhancing patient access to cutting-edge therapies. As the emphasis on personalized cancer care continues to grow, the involvement of specialty clinics in clinical trials is likely to expand significantly, further bolstering the market.

Research Institutes:

Research institutes are at the forefront of developing innovative immuno-oncology therapies through their extensive R&D initiatives. These organizations often collaborate with pharmaceutical companies and healthcare providers to conduct clinical trials that explore new treatment modalities. The emphasis on translational research within these institutes allows for the rapid advancement of findings from laboratories to clinical settings. As the demand for novel cancer therapies increases, research institutes are poised to play a crucial role in driving the immuno-oncology clinical trials market forward through their pioneering work and collaboration efforts.

CROs:

Contract Research Organizations (CROs) provide essential services to support the execution of immuno-oncology clinical trials. These organizations specialize in managing various components of clinical trials, including study design, patient recruitment, data management, and regulatory compliance. The increasing complexity of clinical trials necessitates the expertise of CROs, which can streamline processes and enhance trial efficiency. As pharmaceutical companies look to expedite their drug development timelines, reliance on CROs is expected to grow, significantly impacting the immuno-oncology clinical trials market. The integration of advanced technologies in trial management by CROs also facilitates better data collection and analysis, further driving their importance in the market.

By Region

The North American region holds a dominant position in the immuno-oncology clinical trials market, accounting for nearly 50% of the global market share in 2025. The advanced healthcare infrastructure, extensive investment in research and development, and a plethora of leading pharmaceutical companies contribute to the robust growth experienced in this region. The presence of numerous cancer research centers and a well-established regulatory framework further enhance the capacity for conducting clinical trials. The increasing prevalence of cancer and the growing focus on personalized medicine are expected to drive the North American market at a CAGR of over 10% during the forecast period.

In Europe, the immuno-oncology clinical trials market is anticipated to witness significant growth owing to a supportive regulatory environment and an increasing number of cancer cases. With countries like Germany, France, and the UK leading in clinical research and innovation, the European market is projected to maintain a strong presence in the global landscape. The growing collaboration between academic institutions and pharmaceutical companies is facilitating advancements in immunotherapy, leading to an increase in clinical trial activity. The anticipated growth rate for the European region is expected to be approximately 9% during the forecast period, reflecting the region's commitment to improving cancer treatment options.

Opportunities

The immuno-oncology clinical trials market presents numerous opportunities for growth and innovation. One significant opportunity lies in the development of combination therapies that synergize the benefits of multiple treatment modalities. As researchers continue to explore the interplay between different immunotherapies and traditional treatments, the potential for enhanced efficacy emerges. This growing trend towards combination therapies not only broadens treatment options for patients but also enhances the likelihood of improved clinical outcomes. Pharmaceutical companies that invest in such innovative combinations will likely position themselves favorably in the competitive landscape of immuno-oncology clinical trials.

Another noteworthy opportunity can be found in the increasing focus on precision medicine and personalized treatments. As the understanding of cancer biology improves, researchers are recognizing the importance of tailoring therapies to individual patient characteristics, including genetic profiles and tumor microenvironments. This shift toward personalized oncology is driving the demand for clinical trials that evaluate targeted immunotherapies. Companies that adopt a patient-centric approach in their clinical trial designs and actively engage patients in the research process are likely to attract greater participation and ultimately contribute to better treatment outcomes. This emphasis on personalization not only enhances patient satisfaction but also supports the overall growth trajectory of the immuno-oncology clinical trials market.

Threats

Despite the growth potential, the immuno-oncology clinical trials market faces several threats that could impact its trajectory. One of the primary concerns is the high cost associated with conducting clinical trials, particularly for advanced therapies that require extensive research and development investment. The increasing complexity of trials and the need for sophisticated technology can lead to significant financial burdens on pharmaceutical companies and research institutions. This financial challenge may result in delays or cancellations of promising trials, ultimately hindering the overall progress of immuno-oncology research. Additionally, reimbursement challenges from insurance companies can further complicate the landscape, making it difficult for patients to access cutting-edge therapies.

Another significant threat is the competition from emerging therapies and treatment modalities. As the field of oncology continues to evolve, new treatment options are being introduced, leading to a highly competitive environment. The rapid pace of innovation means that companies must continuously adapt and differentiate their offerings to remain relevant. Failure to do so may result in decreased interest from clinical trial participants and investors alike. Moreover, the potential for adverse effects or negative outcomes in clinical trials can tarnish the reputation of immuno-oncology therapies, impacting patient trust and willingness to participate in future studies. Navigating these competitive pressures will be crucial for stakeholders in the immuno-oncology clinical trials market.

Competitor Outlook

• Bristol Myers Squibb
• Merck & Co., Inc.
• Roche Holding AG
• Pfizer Inc.
• AstraZeneca plc
• Novartis AG
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Sanofi S.A.
• Johnson & Johnson
• Celgene Corporation
• Eli Lilly and Company
• Blueprint Medicines Corporation
• Incyte Corporation

The competitive landscape of the immuno-oncology clinical trials market is characterized by a mix of established pharmaceutical companies and innovative biotech firms. Major players in the industry are heavily investing in R&D activities to develop novel therapies and expand their portfolios. These companies aim to enhance patient outcomes and address unmet medical needs, particularly in underserved cancer populations. Collaboration and partnerships are also prevalent in this market, as organizations seek to leverage each other's expertise and resources to accelerate drug development timelines. The competitive environment is dynamic, with ongoing advancements and new entrants continuously reshaping the landscape.

Among the key players in the market, Bristol Myers Squibb stands out with its robust portfolio of immuno-oncology therapies, including the well-known checkpoint inhibitors, Opdivo (nivolumab) and Yervoy (ipilimumab). These therapies have achieved significant success in treating various cancers, positioning the company as a leader in the field. Merck & Co., Inc. is another prominent player, known for its groundbreaking anti-PD-1 therapy, Keytruda (pembrolizumab), which has set new standards for cancer treatment. The company's commitment to expanding research and exploring combination therapies further solidifies its presence in the immuno-oncology landscape.

Furthermore, Roche Holding AG, with its extensive pipeline of monoclonal antibodies and targeted therapies, is making significant strides in immuno-oncology. The company's innovative approaches to cancer treatment, combined with a strong focus on precision medicine, are driving its success in clinical trials. Pfizer Inc. is also a key player, leveraging its vast resources and expertise to further enhance the development of immuno-oncology therapies. The incorporation of advanced technologies and a patient-centric approach are key factors that differentiate these companies in a competitive market, ultimately contributing to their continued success in the immuno-oncology clinical trials arena.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Novartis AG
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 AstraZeneca plc
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Roche Holding AG
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Johnson & Johnson
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Incyte Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol Myers Squibb
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Eli Lilly and Company
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Gilead Sciences, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Blueprint Medicines Corporation
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Regeneron Pharmaceuticals, Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Immuno-oncology Clinical Trials Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Specialty Clinics
    • 6.1.3 Research Institutes
    • 6.1.4 CROs
  • 6.2 Immuno-oncology Clinical Trials Market, By Cancer Type
    • 6.2.1 Lung Cancer
    • 6.2.2 Breast Cancer
    • 6.2.3 Prostate Cancer
    • 6.2.4 Colorectal Cancer
    • 6.2.5 Melanoma
  • 6.3 Immuno-oncology Clinical Trials Market, By Trial Phase
    • 6.3.1 Phase I
    • 6.3.2 Phase II
    • 6.3.3 Phase III
    • 6.3.4 Phase IV
    • 6.3.5 Phase V
  • 6.4 Immuno-oncology Clinical Trials Market, By Therapy Type
    • 6.4.1 Monoclonal Antibodies
    • 6.4.2 Checkpoint Inhibitors
    • 6.4.3 Cancer Vaccines
    • 6.4.4 Cytokines
    • 6.4.5 Adoptive Cell Transfer Therapy

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Immuno-oncology Clinical Trials Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Immuno-oncology Clinical Trials market is categorized based on

By Trial Phase

• Phase I
• Phase II
• Phase III
• Phase IV
• Phase V

By Therapy Type

• Monoclonal Antibodies
• Checkpoint Inhibitors
• Cancer Vaccines
• Cytokines
• Adoptive Cell Transfer Therapy

By Cancer Type

• Lung Cancer
• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Melanoma

By User

• Hospitals
• Specialty Clinics
• Research Institutes
• CROs

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Bristol Myers Squibb
• Merck & Co., Inc.
• Roche Holding AG
• Pfizer Inc.
• AstraZeneca plc
• Novartis AG
• Gilead Sciences, Inc.
• Regeneron Pharmaceuticals, Inc.
• Amgen Inc.
• Sanofi S.A.
• Johnson & Johnson
• Celgene Corporation
• Eli Lilly and Company
• Blueprint Medicines Corporation
• Incyte Corporation